Eloy Roman, MD
Hematology & Oncology · Miami Lakes, FLNPI 1811018765
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Novartis at 34.2% of the total. Reporting peaked in 2019 at $19,752 and has fallen 76.4% since, to $4,669 in 2025.
Across 1,668 payments — averaging $39.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$23K
- AstraZeneca$10K
- Apellis Pharmaceuticals, Inc.$4K
- Pfizer$3K
- Swedish Orphan Biovitrum AB$2K
- Merck$2K
- plus $22K from 54 others
Across 70 payments — averaging $3550.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$89K
- Apellis Pharmaceuticals, Inc.$47K
- Astrazeneca UK Limited$16K
- Morphosys AG$16K
- Pfizer$16K
- Spectrum Pharmaceuticals Inc.$15K
- plus $50K from 5 others
What the payments were for
- Consulting fees$6,2149%
- Speaking & faculty fees$24,80838%
- Travel & lodging$3731%
- Food & beverage$33,34550%
- Education$1,3472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$66,086 in reported general payments places this provider in the 85th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 70 | $1,003,813 |
| IbrancePalbociclib | 61 | $950,612 |
| LenvimaLenvatinib Mesylate | 38 | $819,418 |
| ImbruvicaIbrutinib | 42 | $653,851 |
| KeytrudaPembrolizumab | 56 | $652,898 |
| XtandiEnzalutamide | 48 | $624,438 |
| FabhaltaIptacopan Hcl | 11 | $489,304 |
| TasignaNilotinib Hcl | 20 | $400,172 |
| Lenalidomide | 29 | $336,808 |
| ErleadaApalutamide | 26 | $322,531 |
| RevlimidLenalidomide | 18 | $248,034 |
| CalquenceAcalabrutinib Maleate | 14 | $206,033 |
| VerzenioAbemaciclib | 14 | $200,429 |
| PromactaEltrombopag Olamine | 15 | $186,753 |
| Azacitidine | 52 | $151,779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisFabhalta, Tasigna, Promacta | $22,603 | $1,076,22946 claims |
| PfizerIbrance, Retacrit, Eliquis | $2,663 | $1,005,019119 claims |
| Beigene USA, Inc.Brukinsa | $543 | $1,003,81370 claims |
| Eisai Inc.Lenvima | $940 | $819,41838 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $457 | $653,85142 claims |
| MerckKeytruda | $2,271 | $652,89856 claims |
| Astellas Pharma US IncXtandi | $678 | $624,43848 claims |
| Johnson & JohnsonErleada, Xarelto | $2,115 | $353,84486 claims |
| AbbVieLupron Depot, Venclexta | $676 | $269,83981 claims |
| Bristol Myers SquibbRevlimid | $1,983 | $248,03418 claims |
| AstraZenecaCalquence | $10,379 | $206,03314 claims |
| Lilly USA, LLCVerzenio | $457 | $200,42914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Miami Lakes
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.